| Literature DB >> 18419812 |
Maija Heiro1, Hans Helenius, Saija Hurme, Timo Savunen, Kaj Metsärinne, Erik Engblom, Jukka Nikoskelainen, Pirkko Kotilainen.
Abstract
BACKGROUND: Only a few previous studies have focused on the long-term prognosis of the patients with infective endocarditis (IE). Our purpose was to delineate factors potentially associated with the long-term outcome of IE, recurrences of IE and requirement for late valve surgery.Entities:
Mesh:
Year: 2008 PMID: 18419812 PMCID: PMC2383901 DOI: 10.1186/1471-2334-8-49
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Association between characteristics of infective endocarditis (IE) and survival (global and in different subgroups) at 2, 5, 10, 15, and 20 years after the admission in 243 episodes of IE in 226 patients who survived over 1 year after the initial episode of IE
| 243 | 95 | 82 | 66 | 51 | 45 | ||
| Male | 174 | 97 | 83 | 68 | 50 | 45 | 0.567 |
| Female | 69 | 91 | 80 | 59 | 51 | 46 | |
| 18–64 years | 172 | 99 | 90 | 76 | 60 | 54 | < 0.001 |
| ≥ 65 years | 71 | 87 | 65 | 38 | 25 | 25 | |
| Aortic | 85 | 95 | 85 | 63 | 52 | 46 | 0.171* |
| Mitral valve | 77 | 95 | 80 | 58 | 40 | 40 | |
| Tricuspid valve | 12 | 100 | 100 | 100 | NA† | NA | |
| Two native valves | 17 | 100 | 100 | 91 | 76 | 76 | |
| Prosthetic valve(s) | 52 | 94 | 74 | 67 | 52 | 43 | |
| | 53 | 98 | 86 | 77 | 57 | 57 | 0.183* |
| Coagulase-negative staphylococci | 22 | 86 | 58 | 41 | 41 | 41 | |
| Viridans streptococci | 50 | 96 | 91 | 77 | 56 | 50 | |
| | 18 | 83 | 83 | 67 | 28 | 28 | |
| | 5 | 100 | 100 | 53 | 53 | 53 | |
| Other | 22 | 95 | 91 | 66 | 60 | 30 | |
| Negative | 73 | 99 | 78 | 61 | 46 | 46 | |
| Acquired valvular disease | 49 | 90 | 70 | 53 | 41 | 36 | 0.019 |
| Prosthetic valves | 55 | 95 | 75 | 66 | 52 | 43 | |
| Bicuspid aortic valve | 26 | 100 | 100 | 94 | 81 | 81 | |
| Mitral valve prolapse | 30 | 97 | 93 | 74 | 62 | 62 | |
| Congenital heart disease | 8 | 100 | 100 | 33 | 33 | NA | |
| No underlying cardiac condition | 75 | 97 | 83 | 63 | 39 | 39 | |
| | |||||||
| Yes | 158 | 96 | 85 | 68 | 53 | 49 | 0.089 |
| No | 85 | 95 | 78 | 61 | 46 | 39 | |
| | 0.162 | ||||||
| Yes | 139 | 95 | 85 | 68 | 52 | 49 | |
| No | 104 | 96 | 80 | 62 | 49 | 41 | |
| | |||||||
| Yes | 21 | 95 | 95 | 77 | 58 | 29 | 0.307 |
| No | 222 | 95 | 81 | 64 | 49 | 45 | |
| | |||||||
| Yes | 5 | 60 | 40 | NA | NA | NA | 0.018 |
| No | 238 | 96 | 83 | 66 | 51 | 46 | |
| | |||||||
| Yes | 14 | 93 | 68 | 24 | 24 | 24 | 0.026 |
| No | 229 | 96 | 83 | 68 | 52 | 46 | |
| | |||||||
| Yes | 11 | 82 | 62 | 31 | NA | NA | 0.004 |
| No | 232 | 96 | 83 | 67 | 53 | 47 | |
| Yes | 19 | 100 | 100 | NA | NA | NA | 0.049 |
| No | 224 | 95 | 81 | 64 | 50 | 44 | |
| Yes | 22 | 91 | 67 | 47 | 35 | NA | 0.029 |
| No | 221 | 96 | 84 | 68 | 53 | 47 | |
| 0.047 | |||||||
| Yes | 108 | 93 | 75 | 55 | 46 | 44 | |
| No | 135 | 98 | 89 | 75 | 55 | 46 | |
| Yes | 60 | 95 | 78 | 66 | 52 | 52 | 0.766 |
| No | 183 | 96 | 84 | 65 | 50 | 43 | |
| Yes | 69 | 97 | 83 | 60 | 50 | 50 | 0.570 |
| No | 174 | 95 | 82 | 67 | 51 | 43 | |
| Yes | 67 | 99 | 89 | 82 | 76 | 73 | < 0.001 |
| No | 176 | 94 | 80 | 59 | 41 | 34 | |
| Surgical | 72 | 99 | 90 | 82 | 74 | 70 | < 0.001 |
| Conservative | 171 | 94 | 79 | 59 | 41 | 33 | |
| Congestive heart failure | 35 | 97 | 85 | 72 | 61 | 55 | 0.002* |
| Valvular regurgitation without heart failure | 18 | 100 | 94 | 94 | 94 | 94 | |
| Dehiscence of prosthetic valve without heart failure | 8 | 100 | 88 | 88 | 88 | 88 | |
| Repeated emboli | 3 | 100 | 100 | 100 | 100 | 100 | |
| Intractable infection | 3 | 100 | 100 | 100 | 100 | 100 | |
| ≥ 50 mm/h | 75 | 93 | 76 | 55 | 40 | 34 | 0.018 |
| < 50 mm/h | 74 | 97 | 89 | 77 | 56 | 53 | |
| ≥ 10 × 109/l | 119 | 97 | 83 | 63 | 41 | 41 | 0.142 |
| < 10 × 109/l | 98 | 94 | 82 | 67 | 61 | 53 | |
| ≥ 100 mg/l | 100 | 96 | 83 | 62 | 48 | 48 | 0.927 |
| < 100 mg/l | 105 | 94 | 80 | 68 | 51 | 43 | |
| < 0.001 | |||||||
| ≥ 100 μmol/l | 76 | 95 | 77 | 53 | 27 | 14 | |
| < 100 μmol/l | 142 | 97 | 87 | 71 | 61 | 59 | |
*p values for overall group differences; †NA = non-applicable, the follow-up did not reach the time point for any patient of the group; ††within 3 months of admission; ‡on admission; §data available for 149 episodes; §Sdata available for 217 episodes; ¶data available for 205 episodes; ¶¶ data available for 218 episodes
Association between characteristics of infective endocarditis (IE) and cardiac mortality at 2, 5, 10, 15, and 20 years after the admission in 243 episodes of IE in 226 patients who survived over 1 year after the initial episode of IE
| 243 | 3 | 10 | 16 | 25 | 29 | ||
| Male | 174 | 2 | 9 | 15 | 26 | 31 | 0.801 |
| Female | 69 | 6 | 11 | 20 | 24 | 24 | |
| 18–64 years | 172 | 1 | 5 | 11 | 22 | 26 | 0.002 |
| ≥ 65 years | 71 | 10 | 21 | 32 | 32 | 32 | |
| Aortic | 85 | 4 | 9 | 18 | 24 | 29 | 0.416* |
| Mitral valve | 77 | 4 | 9 | 20 | 34 | 34 | |
| Tricuspid valve | 12 | 0 | 0 | 0 | NA | NA | |
| Two native valves | 17 | 0 | 0 | 0 | 17 | 17 | |
| Prosthetic valve(s) | 52 | 4 | 17 | 17 | 24 | 29 | |
| | 53 | 2 | 4 | 4 | 4 | 4 | 0.032* |
| Coagulase-negative staphylococci | 22 | 10 | 20 | 30 | 30 | 30 | |
| Viridans streptococci | 50 | 2 | 2 | 9 | 34 | 40 | |
| | 18 | 17 | 17 | 25 | 63 | 63 | |
| | 5 | 0 | 0 | 0 | 0 | 0 | |
| Other | 22 | 0 | 0 | 16 | 16 | 28 | |
| Negative | 73 | 1 | 17 | 22 | 25 | 25 | |
| Acquired valvular disease | 49 | 8 | 19 | 29 | 41 | 41 | 0.015* |
| Prosthetic valves | 55 | 4 | 16 | 16 | 23 | 28 | |
| Bicuspid aortic valve | 26 | 0 | 0 | 0 | 0 | 0 | |
| Mitral valve prolapse | 30 | 3 | 3 | 15 | 29 | 29 | |
| Congenital heart disease | 8 | 0 | 0 | 38 | 38 | NA | |
| No underlying cardiac condition | 75 | 1 | 6 | 12 | 27 | 27 | |
| | |||||||
| Yes | 158 | 3 | 7 | 14 | 22 | 25 | 0.013 |
| No | 85 | 4 | 15 | 22 | 32 | 36 | |
| | 0.007 | ||||||
| Yes | 139 | 4 | 6 | 12 | 22 | 22 | |
| No | 104 | 3 | 15 | 22 | 30 | 36 | |
| | |||||||
| Yes | 21 | 5 | 5 | 5 | 29 | 29 | 0.325 |
| No | 222 | 3 | 10 | 18 | 26 | 30 | |
| | 0.340 | ||||||
| Yes | 5 | 25 | 25 | NA | NA | NA | |
| No | 238 | 3 | 9 | 16 | 25 | 29 | |
| | 0.160 | ||||||
| Yes | 14 | 7 | 24 | 49 | 49 | 49 | |
| No | 229 | 3 | 9 | 15 | 24 | 28 | |
| | |||||||
| Yes | 11 | 10 | 10 | 40 | NA | NA | 0.383 |
| No | 232 | 3 | 10 | 16 | 25 | 28 | |
| Yes | 19 | 0 | 0 | NA | NA | NA | 0.164 |
| No | 224 | 4 | 10 | 17 | 26 | 30 | |
| Yes | 22 | 9 | 15 | 15 | 25 | NA | 0.660 |
| No | 221 | 3 | 9 | 16 | 25 | 29 | |
| Yes | 108 | 6 | 15 | 23 | 28 | 31 | 0.110 |
| No | 135 | 2 | 5 | 11 | 23 | 27 | |
| Yes | 60 | 3 | 11 | 18 | 27 | 27 | 0.930 |
| No | 183 | 3 | 9 | 16 | 25 | 30 | |
| 0.175 | |||||||
| Yes | 69 | 3 | 8 | 14 | 20 | 20 | |
| No | 174 | 3 | 10 | 17 | 27 | 32 | |
| Yes | 67 | 0 | 5 | 7 | 14 | 18 | 0.029 |
| No | 176 | 5 | 12 | 20 | 30 | 34 | |
| 0.026 | |||||||
| Surgical | 72 | 0 | 4 | 9 | 15 | 19 | |
| Conservative | 171 | 5 | 12 | 20 | 30 | 34 | |
| Congestive heart failure | 35 | 0 | 3 | 7 | 22 | 29 | 0.269* |
| Valvular regurgitation without heart failure | 18 | 0 | 6 | 6 | 6 | 6 | |
| Dehiscence of prosthetic valve without heart failure | 8 | 0 | 13 | 13 | 13 | 13 | |
| Repeated emboli | 3 | 0 | 0 | 0 | 0 | 0 | |
| Intractable infection | 3 | 0 | 0 | 0 | 0 | 0 | |
| ≥ 50 mm/h | 75 | 4 | 14 | 23 | 29 | 33 | 0.527 |
| < 50 mm/h | 74 | 1 | 6 | 13 | 30 | 34 | |
| ≥ 10 × 109/l | 119 | 3 | 10 | 17 | 30 | 30 | 0.781 |
| < 10 × 109/l | 98 | 4 | 9 | 17 | 24 | 31 | |
| ≥ 100 mg/l | 100 | 3 | 7 | 10 | 13 | 13 | 0.080 |
| < 100 mg/l | 105 | 4 | 12 | 16 | 28 | 39 | |
| ≥ 100 μmol/l | 76 | 5 | 12 | 24 | 42 | 60 | 0.001 |
| < 100 μmol/l | 142 | 1 | 7 | 13 | 18 | 18 | |
*p values for overall group differences; †NA = non-applicable, the follow-up did not reach the time point for any patient of the group; ††within 3 months of admission; ‡on admission; §data available for 149 episodes; §Sdata available for 217 episodes; ¶data available for 205 episodes; ¶¶ data available for 218 episodes
Figure 1Kaplan-Meier curves of the overall mortality and cardiac mortality for 243 episodes of infective endocarditis in 226 patients, who survived longer than 1 year after the initial episode. The numbers at different time points refer to the number of patients being followed up and at risk for event at the beginning of the time period. Zero on the time access indicates 1 year.
Figure 2Long-term outcome was analysed for 243 episodes of infective endocarditis in 226 patients, who survived longer than 1 year after the initial episode. Kaplan-Meier curves of the overall survival for patients with and without heart failure during 3 months of admission (a), and for those undergoing and not undergoing early (in-hospital) surgery (b). The numbers at different time points refer to the number of patients being followed up and at risk for event at the beginning of the following time period. Zero on the time access indicates 1 year.
Figure 3Kaplan-Meier curves of survival free of recurrent endocarditis, valve replacement, and death after an episode of infective endocarditis. The numbers at different time points refer to the number of patients being followed up and at risk for event at the beginning of the following time period. Zero on the time access indicates 1 year.